Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Angiodynamics (ANGO) EPS (Weighted Average and Diluted) (2016 - 2026)

Angiodynamics' EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at -$0.19 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 72.73% year-over-year to -$0.19; the TTM value through Feb 2026 reached -$0.75, up 25.74%, while the annual FY2025 figure was -$0.83, 81.92% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.19 in Q1 2026 per ANGO's latest filing, down from -$0.15 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.15 in Q3 2023 to a low of -$4.67 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.45, with a median of -$0.24 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 448.48% in 2023, then crashed 1845.83% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.21 in 2022, then plummeted by 242.86% to -$0.72 in 2023, then soared by 63.89% to -$0.26 in 2024, then skyrocketed by 42.31% to -$0.15 in 2025, then dropped by 26.67% to -$0.19 in 2026.
  • Per Business Quant, the three most recent readings for ANGO's EPS (Weighted Average and Diluted) are -$0.19 (Q1 2026), -$0.15 (Q4 2025), and -$0.26 (Q3 2025).